An innovative Covidien
(NYSE: COV) technology is effective at treating Barrett's esophagus (a
precancerous condition of the esophagus), according to a clinical study
published in The Journal of the American Medical Association
The March 25 JAMA publication announced results from the SURF Trial (SUrveillance
ablation). SURF was a multi-center, randomized, investigator-sponsored
clinical trial that compared the Covidien Barrx™ RF Ablation System with
endoscopic surveillance in patients with Barrett's esophagus and a
confirmed diagnosis of low-grade dysplasia. The study enrolled 136
patients at nine European sites between June 2007 and June 2011.
"In patients with Barrett's esophagus containing confirmed low-grade
dysplasia, endoscopic ablation significantly reduced disease progression
to high-grade dysplasia and esophageal cancer as compared to
surveillance alone," said principal investigator Jacques Bergman, M.D.,
Ph.D., professor of Gastrointestinal Endoscopy, director of Endoscopy,
Academic Medical Center, Amsterdam, The Netherlands. "The difference in
the disease progression outcome between the two groups was so large, in
fact, that the data safety monitoring board overseeing the trial
recommended early stoppage of the trial and patients in the contol
group were then offered endoscopic ablation."
Barrett's esophagus develops as a result of chronic injury from
gastroesophageal reflux disease (GERD). The normal esophageal lining is
replaced with abnormal cells (known as Barrett's tissue), putting
patients at greater risk of developing cancer of the esophagus. Patients
with Barrett's who ultimately develop cancer typically do so through a
series of steps, starting with early Barrett's, then low-grade dysplasia
or high-grade dysplasia and then cancer.
The SURF Trial was supported, in part, by a grant from Covidien GI
Solutions and the Maag Lever Darm Stichting grant (WO 07-06) from the
Dutch Digestive Diseases Foundation.
Covidien's Barrx RF Ablation System is used as part of an endoscopic
(non-surgical) procedure and uses radiofrequency energy to coagulate
tissue and remove the Barrett's epithelial tissue. In the United States,
the Barrx system is indicated for use in the coagulation of bleeding and
non-bleeding sites in the gastrointestinal tract including but not
limited to, the esophagus. Indications include Esophageal Ulcers,
Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's
Esophagus, Dieulafoy Lesions, and Angiodysplasia.
For more information on Barrett's Esophagus, GERD, treatment options and
patient success stories please visit http://treatbarretts.com/.
For more information on the JAMA publication and news release please
Covidien is a leading global health care products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien develops,
manufactures and sells a diverse range of industry-leading medical
device and supply products. With 2013 revenue of $10.2 billion, Covidien
has more than 38,000 employees worldwide in more than 70 countries, and
its products are sold in over 150 countries. Please visit www.covidien.com
to learn more about our business.
[ Back To NFVZone's Homepage ]